|
Transgenic manipulation is the name of the game at GTC Biotherapeutics. The firm makes its products by inserting human DNA into animals who then produce the protein in their milk; the proteins are purified from the milk and used for human treatments. This process of creating what are known as recombinant proteins makes it easier and cheaper to produce large quantities of certain therapeutic proteins. The company's lead candidate ATryn received European regulatory approval in 2006 and FDA approval in 2009; the product is a recombinant human antithrombin, which has anticoagulant and anti-inflammatory properties that help prevent blood clots. French firm LFB Biotechnologies owns about 20% of GTC.
|
| | | Contact Information | |
Address: |
175 Crossing Blvd., Ste. 410
Framingham, MA 01702-9322
| | Phone: | 508-620-9700 | | Fax: | 508-370-3797 |
|
| Financial
Highlights | | Fiscal Year End: | December | | Revenue (2008): | 16.70 M | | Revenue Growth (1 yr): | 19.90% | | Employees (2008): | 159 | | Employee Growth (1 yr): | (-10.70%) |
|
|
Key People
| | • |
Chairman, President, and CEO:
Geoffrey F. Cox
| | • |
SVP, CFO, and Treasurer:
John B. Green
| | • |
VP Business Development:
Ashley Lawton
|
|
|
